D Orazio & Associates Inc. Makes New Investment in Puma Biotechnology, Inc. $PBYI

D Orazio & Associates Inc. bought a new stake in shares of Puma Biotechnology, Inc. (NASDAQ:PBYI) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 15,027 shares of the biopharmaceutical company’s stock, valued at approximately $52,000.

Several other hedge funds and other institutional investors have also recently modified their holdings of PBYI. CWM LLC raised its stake in shares of Puma Biotechnology by 214.1% during the second quarter. CWM LLC now owns 9,462 shares of the biopharmaceutical company’s stock valued at $32,000 after acquiring an additional 6,450 shares in the last quarter. Savant Capital LLC purchased a new position in Puma Biotechnology during the 2nd quarter worth $44,000. Causeway Capital Management LLC bought a new stake in Puma Biotechnology during the 1st quarter valued at $42,000. Ethic Inc. purchased a new stake in shares of Puma Biotechnology in the 2nd quarter worth $51,000. Finally, Kathmere Capital Management LLC purchased a new stake in shares of Puma Biotechnology in the 2nd quarter worth $69,000. 61.29% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, Director Michael Patrick Miller sold 20,000 shares of the stock in a transaction on Tuesday, November 11th. The stock was sold at an average price of $4.86, for a total transaction of $97,200.00. Following the completion of the sale, the director owned 54,000 shares in the company, valued at approximately $262,440. This represents a 27.03% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 23.30% of the stock is currently owned by company insiders.

Puma Biotechnology Trading Down 0.8%

Shares of NASDAQ PBYI opened at $4.95 on Friday. Puma Biotechnology, Inc. has a 1-year low of $2.32 and a 1-year high of $6.12. The business has a fifty day moving average price of $5.01 and a 200 day moving average price of $4.16. The stock has a market capitalization of $249.34 million, a P/E ratio of 5.05 and a beta of 1.35. The company has a debt-to-equity ratio of 0.10, a current ratio of 1.73 and a quick ratio of 1.62.

Puma Biotechnology (NASDAQ:PBYI) last announced its earnings results on Thursday, November 6th. The biopharmaceutical company reported $0.21 EPS for the quarter, topping analysts’ consensus estimates of $0.09 by $0.12. Puma Biotechnology had a net margin of 20.38% and a return on equity of 53.15%. The business had revenue of $54.48 million during the quarter, compared to the consensus estimate of $51.00 million. Puma Biotechnology has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. Equities research analysts expect that Puma Biotechnology, Inc. will post 0.31 EPS for the current fiscal year.

Analysts Set New Price Targets

Several analysts recently weighed in on PBYI shares. Wall Street Zen downgraded Puma Biotechnology from a “strong-buy” rating to a “buy” rating in a report on Saturday, November 8th. Weiss Ratings lowered shares of Puma Biotechnology from a “buy (b-)” rating to a “hold (c+)” rating in a report on Saturday, October 25th. One equities research analyst has rated the stock with a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat, Puma Biotechnology presently has an average rating of “Moderate Buy” and an average price target of $7.00.

About Puma Biotechnology

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.